Connection

GABRIEL LOPEZ to Candidiasis

This is a "connection" page, showing publications GABRIEL LOPEZ has written about Candidiasis.
Connection Strength

0.993
  1. Liposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo. J Infect Dis. 1991 Nov; 164(5):1003-6.
    View in: PubMed
    Score: 0.082
  2. Antifungal activity of HWA-138 and amphotericin B in experimental systemic candidiasis. Antimicrob Agents Chemother. 1991 Oct; 35(10):2046-8.
    View in: PubMed
    Score: 0.082
  3. Attenuation of amphotericin-B nephrotoxicity in the candidiasis rat model. Nephron. 1991; 59(1):139-44.
    View in: PubMed
    Score: 0.078
  4. Enhancement of the treatment of experimental candidiasis with vascular decongestants. J Infect Dis. 1990 Jul; 162(1):211-4.
    View in: PubMed
    Score: 0.075
  5. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother. 1987 Dec; 31(12):1897-900.
    View in: PubMed
    Score: 0.063
  6. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother. 1987 Dec; 31(12):1901-3.
    View in: PubMed
    Score: 0.063
  7. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol. 1987 Feb; 5(2):310-7.
    View in: PubMed
    Score: 0.059
  8. Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology. 1986 May; 159(2):349-53.
    View in: PubMed
    Score: 0.056
  9. Prophylaxis of Candida albicans infection with tuftsin. J Antimicrob Chemother. 1986 Mar; 17(3):361-3.
    View in: PubMed
    Score: 0.056
  10. Protective effect of liposomal-amphotericin B against C. albicans infection in mice. Cancer Drug Deliv. 1985; 2(3):183-9.
    View in: PubMed
    Score: 0.051
  11. Liposomal polyene antibiotics. Methods Enzymol. 2005; 391:304-13.
    View in: PubMed
    Score: 0.051
  12. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis. 1984 Aug; 150(2):278-83.
    View in: PubMed
    Score: 0.050
  13. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv. 1984; 1(3):199-205.
    View in: PubMed
    Score: 0.048
  14. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983 May; 147(5):939-45.
    View in: PubMed
    Score: 0.046
  15. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv. 1983; 1(1):37-42.
    View in: PubMed
    Score: 0.045
  16. Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice. Antimicrob Agents Chemother. 1994 Feb; 38(2):356-9.
    View in: PubMed
    Score: 0.024
  17. Evaluation of amphotericin B-cyclosporine interaction in the rat. Transplantation. 1990 Sep; 50(3):506-10.
    View in: PubMed
    Score: 0.019
  18. Liposomes as carriers of antifungal drugs. Ann N Y Acad Sci. 1988; 544:590-7.
    View in: PubMed
    Score: 0.016
  19. Prophylaxis of murine candidiasis via application of liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination. Antimicrob Agents Chemother. 1985 Oct; 28(4):511-3.
    View in: PubMed
    Score: 0.014
  20. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr; 151(4):704-10.
    View in: PubMed
    Score: 0.013
  21. Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections. Ann N Y Acad Sci. 1985; 446:390-402.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.